AstraZeneca's combo lung disease therapy falls short of FDA approval
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combo therapy to treat a form of lung disease, the drugmaker said on Tuesday.
from Reuters: Health News https://ift.tt/2nmOODc
from Reuters: Health News https://ift.tt/2nmOODc
Comentarii
Trimiteți un comentariu